Table 2.

Demographics of HALT study participants.

Variable	N = 119
Age, mean ± standard deviation (SD)	57 ± 13
Female recipient, n (%)	49 (41%)
Diagnosis, n (%)
COPD	38 (32%)
Interstitial lung disease / pulmonary fibrosis	53 (44%)
Cystic fibrosis (CF) or non-CF bronchiectasis	18 (15%)
Pulmonary hypertension	2 (2%)
Other	8 (7%)
Lung allocation score at transplant, mean ± SD	45.59 ± 16.93
Pre-transplant ECMO support	2 (2%)
Bilateral lung transplant, n (%)	90 (76%)
Single lung transplant, n (%)	29 (24%)
Intraoperative cardiopulmonary bypass, n (%)	69 (58%)
Ischemic time (minutes), mean ± standard deviation	285 ± 80
Post-transplant ECMO support, n (%)	1 (1%)
Identical donor-recipient ABO status, n (%)	107 (90%)
Compatible donor-recipient ABO status, n (%)	12 (10%)
Recipient CMV seropositive, n (%)	53 (45%)
Recipient CMV seronegative and donor seropositive, n (%)	35 (29%)
Pre-transplant DSA, n (%)	12 (10%)
Number of donor-recipient mismatches at HLA A, B, C, DRB1, and DQB loci, median (IQR)	8 (3)
Number of donor-recipient mismatches at HLA-DRB1 locus, median (IQR)	2 (1)
Number of donor-recipient mismatches at HLA-DQB locus, median (IQR)	1 (1)
Positive Flow Cytometry B-cell crossmatch, n (%)	17 (15%)
PGD grade at time 0*, n (%)
PGD 0	69 (60%)
PGD 1	26 (23%)
PGD 2	10 (9%)
PGD 3	10 (9%)
PGD grade at 72 hours**, n (%)
PGD 0	49 (47%)
PGD 1	49 (47%)
PGD 2	3 (3%)
PGD 3	4 (4%)
Blood product transfusion during transplant hospitalization, n (%)	63 (53%)
Induction immunosuppression, n (%)
None	45 (38%)
Basiliximab	72 (60%)
Rabbit anti-thymocyte globulin	2 (2%)

COPD: chronic obstructive pulmonary disease, with or without alpha 1-antitrypsin deficiency

ECMO: extracorporeal membrane oxygenation

CMV: cytomegalovirus

PGD: primary graft dysfunction

^*Immediately after transplantation (time 0), 115 recipients had sufficient data to calculate PGD grades

^**At 72 hours, 105 recipients had sufficient data to calculate PGD grades